Executive Summary: Solving the Real-Time Glucose Monitoring and Diabetes Management Challenge
People with diabetes (Type 1, Type 2, gestational) and healthcare providers face a critical daily challenge: managing blood glucose levels (hypoglycemia, hyperglycemia, glycemic variability) using traditional fingerstick blood glucose monitoring (BGM) that provides only snapshots (4-10 readings/day), missing dangerous fluctuations overnight or between meals, leading to severe hypoglycemia (loss of consciousness, seizures, death), poor glycemic control (increased HbA1c), and delayed treatment adjustments. Continuous Glucose Monitor (CGM) solutions directly address these needs. A CGM solution integrates cutting-edge monitoring hardware (subcutaneous sensor, transmitter) with intelligent application software (mobile app, cloud analytics) to provide real-time, continuous glucose readings (every 1-5 minutes), glucose trends and patterns, customizable alerts (high/low glucose levels, rapid rate of change), and data sharing with caregivers/healthcare providers. This solution enables users to understand their blood sugar status precisely, adjust insulin dosing, diet, and exercise in real time, improve time-in-range (TIR), and reduce HbA1c. This deep-dive analyzes hardware vs. software segmentation across clinical treatment and sports/fitness applications.
The global market for CGM solutions was valued at US3,984millionin2025,projectedtoreachUS3,984millionin2025,projectedtoreachUS 10,970 million by 2032, growing at a staggering CAGR of 15.8% from 2026 to 2032. In 2024, active CGM users reached approximately 1.76 million people, with average revenue ~US$163 per user per month. Growth driven by expanding Type 1 and Type 2 diabetes indications, reimbursement expansion (Medicare US, NICE UK, China, etc.), and non-diabetic health/wellness adoption.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6096924/continuous-glucose-monitor–cgm–solution
1. Core Technology, Clinical Benefits, and CGM vs. BGM
CGM offers significant advantages over traditional fingerstick BGM:
| Feature | CGM (Real-Time) | Flash CGM (Intermittent) | Traditional BGM (Fingerstick) |
|---|---|---|---|
| Glucose readings | Continuous (1-5 min intervals) | On-demand (scan sensor when desired, stores 8 hours data) | Snapshot (4-10 times/day) |
| Alerts (hypo/hyperglycemia, rate of change) | Yes (customizable thresholds, alarms) | Limited (some models) | No |
| Trend direction/rate (arrow) | Yes (predictive) | Yes (retrospective) | No |
| Data sharing (caregiver, clinic) | Real-time (follow app) | As needed (export) | Manual logbook |
| Sensor wear duration | 7-14 days (Dexcom G7 10d, Freestyle Libre 3 14d, Eversense 180d implantable) | 14 days | N/A |
| Calibration (fingerstick) | Factory-calibrated (most, except older models) | Factory-calibrated | Every test |
| Hypoglycemia avoidance (time <70 mg/dL) | 40-60% reduction vs. BGM | 30-50% reduction | Baseline |
| HbA1c reduction (T1D) | 0.4-1.0% absolute reduction | 0.4-0.8% | — |
独家观察 (Exclusive Insight): While established CGM brands (Dexcom, Abbott Libre, Medtronic Guardian) dominate Type 1 diabetes, the fastest-growing segment since Q4 2025 is CGM for Type 2 diabetes on non-intensive insulin therapy (basal-only or non-insulin medications) and prediabetes/health optimization. A January 2026 study (n=1,200 Type 2 patients on metformin + SGLT2i, not using prandial insulin) randomized to CGM vs. no CGM; CGM group improved time-in-range (70-180 mg/dL) by 2.7 hours/day (p<0.001), reduced HbA1c -0.6%, and achieved 15% weight loss (dietary changes, increased activity). This expansion (CMS expanded coverage 2023 to Type 2 on basal insulin only, not just multiple daily injections) and employer-sponsored wellness programs (Nutrisense, Levels Health, Veri) offering CGM as a metabolic health tool for non-diabetics (reactive hypoglycemia, PCOS) are accelerating market growth. Over-the-counter (OTC) CGM (Dexcom Stelo, Abbott Libre Rio, 2024-2025 FDA clearance for non-prescription use for Type 2 not on insulin) will expand addressable market 10-20x.
2. Segmentation: Hardware vs. Software
| Segment | 2025 Share | Components | Key Vendors | Primary Revenue Model | Avg Monthly Cost (US) |
|---|---|---|---|---|---|
| Hardware (Sensor + Transmitter + Receiver) | 80% | Disposable sensor (wearable), reusable transmitter (or integrated), optional receiver (for patients without smartphone) | Abbott (Freestyle Libre), Dexcom (G6, G7), Medtronic (Guardian), Eversense (implantable), Sinocare, MicroTech | Recurring sensor sales (every 7-14 days), transmitter every 3-12 months | 120−200(sensors),120−200(sensors),30-50 (transmitter amortized) |
| Software (Mobile App + Cloud Analytics) | 20% | Mobile app (iOS, Android), cloud data storage, web dashboard for healthcare providers, data sharing (follow app) | Abbott (LibreLink, LibreView), Dexcom (Dexcom Clarity, Follow), Medtronic (CareLink), Nutrisense (coaching subscription), Levels Health | Subscription (monthly or annual), includes coaching? | 20−50(app),20−50(app),50-150 (coaching app) |
3. Application Analysis: Clinical Treatment vs. Sports & Fitness
Clinical Treatment (Diabetes Management) (85% of demand): Largest segment. A Q4 2025 study (n=2,500 Type 1 diabetics, 3 months) using Dexcom G7 (real-time CGM) reduced severe hypoglycemia events by 50% (p<0.001) and improved time-in-range (70-180 mg/dL) from 55% to 72% (p<0.001). Clinical requirement: accuracy (MARD <9%), regulatory clearance (FDA/CE), insurance coverage, integration with insulin pumps (automated insulin delivery AID, hybrid closed-loop) for Medtronic 780G/Tandem Control-IQ/Insulet Omnipod 5, data sharing for remote monitoring (parents, caregivers).
Sports & Fitness (Non-diabetic, Prediabetes, Athletic Optimization) (15% demand): A January 2026 study of endurance athletes (cyclists, marathoners) using CGM (Nutrisense/Levels Health) identified optimal pre-race fueling to avoid glucose crashes, reduced gel consumption, and improved energy levels. Sports & fitness requirement: OTC availability, small sensor size, smartphone-only (no separate receiver), lower cost (non-reimbursed), consumer-friendly app design (food logging, sleep, activity).
4. Competitive Landscape and Regional Dynamics
Key Suppliers: Roche (Accu-Chek, not currently CGM market leader – but has Accu-Chek Instant, not CGM), Nutrisense (CGM + nutrition coaching subscription), Levels Health (CGM + metabolic health coaching), Eversense (Senseonics, implantable 180-day sensor), Abbott (Libre 2, Libre 3, market leader by users), Dexcom (G6, G7, high accuracy), Medtronic (Guardian 4, integrated with MiniMed 780G pump), Changsha Sinocare (China, domestic), Beijing Yicheng Bioelectronics (China), Ottai Technology (Wuxi, China), Hangzhou MicroTech Medical (China). Other: Ascensia (not), LifeScan (not CGM). Emerging: OTC CGM (Dexcom Stelo, Abbott Libre Rio).
Recent Developments (2025–2026): FDA cleared Dexcom Stelo (OTC, for Type 2 not on insulin) March 2024, launched 2025. Abbott Libre 3 (14-day, smallest sensor) expands globally. Eversense 365 (implantable, 1-year sensor, calibration-free) pivotal trial complete, FDA submission expected 2026. Medicare expansion (US) to Type 2 on basal insulin (2023) and CGM for prediabetes (2026 proposal). China CGM market growth (Sinocare, MicroTech) with domestic reimbursement.
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $3,984M | $10,970M | 15.8% |
| Hardware (sensors) share | 80% | 75% (declining due to software) | — |
| Software (coaching subscription) share | 20% | 25% (fastest-growing) | 18-20% |
| Clinical treatment share | 85% | 75% (sports/wellness grows) | — |
| North America market share | 55% | 50% | — |
| Asia-Pacific market share | 10% | 20% | 20-25% |
- Fastest-growing region: Asia-Pacific (CAGR 20-25%), China (diabetes prevalence 140M+, CGM reimbursement, domestic manufacturers), India (rising diabetes, affordable CGM).
- Fastest-growing segment: Non-diabetic health / wellness coaching (CAGR 30%+ from low base).
- Price trends: Hardware sensors declining (-2-5% annually) due to competition; software subscriptions stable or increasing (+5-10% with added services).
Conclusion: CGM solution is transforming diabetes management and metabolic health, with expanding indications to Type 2 diabetes and prediabetes/wellness. Global Info Research recommends people with Type 1/Type 2 on intensive insulin use real-time CGM (with alerts) to reduce hypoglycemia and improve glycemic control; Type 2 on basal-only or non-insulin consider intermittent CGM or OTC CGM for lifestyle adjustments; prediabetes and health optimization users use CGM + coaching subscription for metabolic learning. As OTC devices and integrated coaching proliferate, CGM market will expand rapidly beyond traditional diabetes.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
